Australian Agricultural Co Ltd (ASAGF) (FY 2025) Earnings Call Highlights: Record Cash Flow ...
Release Date: May 21, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Australian Agricultural Co Ltd (ASAGF) achieved its highest operating cash flow and second highest operating profit since 2017.
The company reported a 15% increase in total sales revenue, driven by higher meat and cattle sales volumes.
ASAGF's strategic refresh and focus on sustainability initiatives, such as the solarable program and soil carbon project, are expected to provide long-term benefits.
The company maintained a stable herd size with improved productivity, contributing to increased revenue.
ASAGF's brands, including West Home and Darling Downs, showed significant sales growth and market expansion.
The company reported a statutory net loss of $1.1 million, impacted by the unrealized mark-to-market value of the herd.
Inflationary pressures led to a 5% increase in the cost of production per kilo.
Price pressures in some regions resulted in an overall reduction in the weighted average meat sales price per kilogram.
The company faced challenges from dynamic markets, evolving trade conditions, and supply and demand constraints.
An unfortunate animal welfare incident occurred earlier in the year, highlighting the need for improved procedures to prevent future occurrences.
Warning! GuruFocus has detected 7 Warning Signs with ASAGF.
Q: With gearing levels at the lower end of the company's target range and the stock trading at a 43.5% discount to NTA, has a buyback been considered? A: Dave Harris, MD and CEO: The decision regarding a share buyback is for the board to make. Currently, the focus is on reinvesting in the business to develop the three strategic business areas, which we believe will provide long-term benefits for shareholders.
Q: What is the strategy for debt reduction and future dividend payments? A: Glenn Steadman, CFO: With the strategic refresh, we have identified areas requiring future investment. Therefore, debt reduction is unlikely as we pursue these investment opportunities.
Q: Can you please advise how many franking credits AAC has? How much possible fully franked dividend per share does this represent? Why does AAC have a policy of not paying dividends, and when is it likely a dividend may be paid? A: Dave Harris, MD and CEO: Currently, there are zero franking credits. The decision on dividends is for the board. Regarding the unfortunate incident where cattle died due to a water supply failure, we have conducted an investigation and developed procedures to minimize the likelihood of such an event occurring again.
Q: What were the impacts, if any, of the heavy rain and Northern Queensland floods in March? How is the pasture since the floods? A: Dave Harris, MD and CEO: The property most affected was South Galway, experiencing significant flooding. Fortunately, there were minimal cattle losses, and the rain was beneficial overall, putting us in good shape for the season ahead.
Q: Post-liberation Day, what have you witnessed with respect to trade flows and pricing, and how is AAC positioning itself given likely ongoing volatility? A: Dave Harris, MD and CEO: We focus on controllable factors, working with distributors and customers in each region. Our broad marketing opportunities allow us to move products through different markets as conditions change, ensuring the best outcomes for both customers and the business.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
26 minutes ago
- Miami Herald
Amazon bets on low prices to win grocery share
What is your biggest concern as a U.S. citizen right now? Rising prices, tariff policies, possible recession, job security, international conflicts, cost and accessibility of health care, or something else? These are all reasonable and important matters to be worried about right now. In fact, as many as 43% of consumers confirmed rising prices as their top concern, followed by tariff uncertainties (29%), according to a McKinsey and Company survey conducted in May. Don't miss the move: Subscribe to TheStreet's free daily newsletter The following biggest concerns include the ability to make ends meet (22%), immigration (19%), and cost and accessibility of health care (16%). This shouldn't come as a surprise, considering that Trump's "Liberation Day" announcement of higher tariff rates has shaken up the country. There is a possibility that tariffs may push the economy into recession. Related: Kroger announces big store change amid price gouging accusations As many as 60% of surveyed consumers have either changed or plan to change their spending habits because of recent tariff developments. Those who plan to change explained they will cut back spending on nonessential items, or switch to lower-priced brands and products. What does this mean for retailers? It means that they need to compete more aggressively on price to win customers. Now, the e-commerce giant, which already has had a disruptive impact on the global retail industry, is aiming to win a significant share of the grocery market. Image source: Ryder/Bloomberg via Getty Images Amazon's (AMZN) subsidiary Amazon Fresh was launched in 2007 as a grocery delivery service. However, in 2020, the company opened its first physical location in the Woodland Hills neighborhood of Los Angeles. In less than two years, there were 38 locations across multiple states. As of May 22, there are 65 Amazon Fresh stores in the United States, with around 42% of them in California. Related: Amazon's latest big bet may flop In 2023, the company announced it has paused the chain's expansion until it sees more favorable results in its grocery segment. Less than a year later, it launched a new store design and upgraded its offering. More recently, Amazon CEO Andy Jassy explained how tariffs might actually positively affect his company, as rivals will see a bigger impact, reported TheStreet's Daniel Kline. More Retail: Huge retail chain closing more stores soon (locations revealed)Struggling drugstore chain announces second bankruptcyBeloved discount grocery chain has massive US plans "When you have the broadest selection like we do, and 2 million-plus global sellers like we do, you're better positioned to help customers find whatever items matter to them at lower price points than elsewhere," he said. Now, Jassy is putting his words into action. Amazon Fresh has lowered many food prices and is loud about it. Many common, brand-name items are priced much lower than they are in nearby stores, and there are plenty of bright red low-price signs inside and outside stores on the East and West coasts, reported Grocery Dive, whose journalists visited three locations. Related: Costco goes bananas to protect members from tariffs One example is an 8-ounce tub of Philadelphia cream cheese, which was priced at $3.49 on May 27 in an Amazon Fresh store in Bellevue, Washington, compared to $4.99 in a Kroger-owned QFC across the street. The same Amazon store was charging $6.99 for a 12-pack of Pepsi cans, while at QFC, the same pack cost $10.99. Further, produce prices at Amazon Fresh store in Alexandria, Virginia, were also more affordable than at the nearest Giant Food store. For example, while Amazon Fresh was charging $1.89 for a 1-pound package of strawberries, Giant Good was charging $4.99, or $3.79 for members of the company's loyalty program. "As part of our focus on offering customers low, competitive prices to save money every day, we work to meet or beat competitor prices across the vast selection of products in our stores," Amazon spokesperson Molly McWhinnie told Grocery Dive in an emailed statement. Amazon's aggressive price competition showcases the giant's intention to better position itself in the oversaturated grocery business segment. Considering that 43% of consumers are worried about price and 60% plan to change their spending habits, this plan just might work. Related: Walmart makes surprise cuts as it looks at tariff price hikes The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
37 minutes ago
- Yahoo
Does Solana Need Its Own Michael Saylor and Strategy?
Does Solana Need Its Own Michael Saylor and Strategy? originally appeared on TheStreet. For the last five years, Michael Saylor has been synonymous with one of the boldest Bitcoin bets in financial history — transforming MicroStrategy into a proxy Bitcoin ETF before one even existed. Now, a new playbook is being written and this time, it's not Bitcoin that's the focus — it's Solana. 'There are so many institutional investors who prefer equities,' said Matt Sigel, Head of Digital Asset Research at VanEck. 'A big part of it is the governance and disclosure is standardized… those securities can fit right alongside a typical equity portfolio.' VanEck has been leading the charge on the institutional front, filing for the first Solana ETF in June last year and continuing to await updates as the U.S. gears up for what could be a post-Gensler regulatory reset. But before that milestone, there's a race underway in the public markets — one that mirrors the early days of Bitcoin's treasury strategy boom. At the center of it is DeFi Dev Corp, a company modeled loosely after MicroStrategy, but with its own twist. 'We kind of think of it as the MicroStrategy 2.0,' said Parker White, COO of DeFi Dev Corp. 'Because Solana is a native yield asset and it's this kind of fuel inside of this whole DeFi ecosystem, there's a bunch of things that you can do with Solana… to generate extra yield as opposed to Bitcoin, which… kind of sits in a vault.' White says the goal is simple: 'We believe we can stack SOL faster than any other entity on the planet.' But expectations are high. According to Sigel, 'MicroStrategy famously trades at about 100% premium to the value of its Bitcoin. There's three Solana treasury companies more or less. They're trading at 4- to 6-times the value of their Solana.' That has since come down a bit as Solana's price has retreated the past few weeks. But nonetheless, that kind of market premium reflects a growing appetite for exposure — not just to Solana as a token, but to the broader thesis that it might become the winning Layer-1 blockchain in a crowded field. 'We think the most likely scenario is that most of the economic activity on open source blockchains will consolidate into one or a small handful of Layer-1s,' Sigel said. 'We think [Solana] has the best shot of becoming that leading blockchain.' Part of that optimism comes from real technical performance. But another part is just plain memetics. Sigel predicted late last year that Solana could surpass $500 per coin in 2025. 'How strong is the culture [and] meme-ability?' Sigel asked rhetorically. 'It's really validating to the thesis to have now three public companies that have committed to that treasury strategy.' That said, it is still early — both in Solana's life cycle and in DeFi Dev Corp's. The company's job now, as White sees it, is to get traditional investors off zero. 'People ask, 'Hey, what are you guys doing?' [We say] 'Hey, we're the best way to accumulate Solana.' And they're like, 'Cool, what's Solana?'' While Bitcoin had to battle skepticism in its early days, Solana now benefits from having a clearer financial playbook to follow — but it also comes with unique challenges. For one, ETFs tied to staked assets raise fresh tax and regulatory questions. 'There's still some operational details around how to manage a staked Solana ETF that we don't have answers to,' Sigel noted. 'Unfortunately, that information needs to come from the IRS… staking and undertaking the Solana that would theoretically be inside of one of these ETFs… that's a form of active management that we think can blow up the tax status.' But even with that uncertainty, Sigel sees the writing on the wall. 'Once that happens, all of the U.S.-based broker-dealers will be touching these assets directly… and I think the biggest impact will be in the derivatives market.' In Sigel view, Solana doesn't necessarily need a Saylor — but it needs someone who understands risk, timing, and volatility. 'Most crypto bull markets kind of end in a blow-off leverage top. There's no balance sheets right now that are really providing that,' he said, noting that traditional finance could step in to fill the vacuum left by collapsed crypto lenders like BlockFi and Celsius. Still, White isn't putting a stake in the ground like Saylor did with his pledge to 'never sell' his Bitcoin. 'I wouldn't put a guidepost on the other side and guarantee that we'll sell" White said. 'But if [our stock] gets deep enough [into a discount], I think we'd have to take a pretty serious look at returning value to shareholders. It could be in the form of buybacks, it could also be… a SOL-denominated dividend.' The one thing he's certain of? Survival matters more than hype. 'The winners in this model will not be determined in the bull market,' White said. 'They will be determined in the bear market… you want to look at a team that's going to be around for the long haul.' Does Solana Need Its Own Michael Saylor and Strategy? first appeared on TheStreet on Jun 9, 2025 This story was originally reported by TheStreet on Jun 9, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Merck claims study success with PCSK9 cholesterol pill
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental cholesterol-lowering pill from Merck & Co. succeeded in a pair of late-stage studies, the company said Monday. In one study, Merck's drug, enlicitide, was tested against a placebo in people already taking statins and who have either an inherited condition that causes high cholesterol or are at risk of atherosclerosis. The second trial evaluated enlicitide against other oral therapies, such as ezetimibe, in people on statins and with abnormally high levels of fats in the blood. Merck didn't provide specifics, but said in both cases enlicitide met all of its study objectives and demonstrated 'statistically significant and clinically meaningful reductions' in LDL-C, or 'bad' cholesterol, without any important differences in the number of adverse events. Details will be presented at a future medical meeting. Company shares climbed 2% in early trading Monday. A decade ago, the Food and Drug Administration approved a pair of injectable treatments that could dramatically lower cholesterol in people with heart disease. The drugs, known as PCSK9 inhibitors for the cholesterol-regulating protein they target, were hailed as medical breakthroughs and billed as multibillion-dollar sellers. Instead, their developers struggled to convince payers and physicians of their worth. Sales totals, until recently, have largely disappointed. Merck believes it will have better luck with enlicitide, which could be the first oral medication that blocks PCSK9. The company has bet heavily on its future, enrolling about 17,000 participants across several late-stage studies. And it's counting on enlicitide to become one of the products that can help it grow sales once the patents protecting Keytruda, its dominant cancer immunotherapy, expire later this decade. Questions about its post-Keytruda future have spurred a 40% share slide over the last year and heightened pressure on its next prospects to succeed. The company, for its part, has spoken boldly about enlicitide's promise. Research chief Dean Li has described it as likely becoming the first of its kind available, the 'most effective' cholesterol-lowering pill medicine on the market, and the foundation for future drug combinations. Enlicitide should also be able to sidestep the reimbursement issues long weighing down sales of PCSK9 blockers, CEO Robert Davis said during a presentation in January. Though the drug is a so-called macrocyclic peptide and thus more complicated to make than traditional small molecule pills, Merck has invested significantly in production and believes it can manufacture enlicitide at a low cost. That could help the company 'price it in a way that won't create the excess challenges' others have had and obtain a 'competitive advantage,' Davis said. Still, there is a large collection of branded and generic cholesterol drugs available, as well as multiple newer medicines in advanced testing. AstraZeneca, for one, has a PCSK9 pill in development that some analysts believe to be a meaningful threat to Merck's program. While there are 'early signs' Merck's drug might be more effective, AstraZeneca's could be 'more tolerable and easier to administer,' Leerink Partners analyst Daina Graybosch wrote in April. The size of enlicitide's effects in Phase 3 testing, then, will be closely scrutinized. In Phase 2 trials, a variety of enlicitide doses lowered LDL levels by up to 60% after eight weeks of treatment. One of the Phase 3 studies Merck reported on Monday tested cholesterol levels after 24 weeks, and there is typically a 'degradation in efficacy' when companies move a drug into larger, longer trials, wrote Jefferies analyst Dennis Ding. Ding also speculated that drug adherence could be lower in Merck's studies, as food intake disrupts enlicitide effectiveness. 'The magnitude of benefit will be key to watch,' he wrote.
